Now approved
in the U.S.

EMPAVELI (pegcetacoplan) injection 1080mg / 20mL solution

Please see full Prescribing Information, including Boxed WARNING and Medication Guide.

US-CORP-2100013, v1.0, 05/14

Fearlessly Advancing

FEARLESSLY
ADVANCING

the first potential treatment
in geographic atrophy

Learn More
Leaders in Complement

LEADERS IN
COMPLEMENT

at the forefront of targeted
C3 therapies

Learn More

With courageous science, creativity, and compassion,
we are committed to delivering therapies for people with
complement-driven diseases.

About Us
Folded page of a newspaper

Latest news

May 25, 2021

Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

May 14, 2021

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

May 12, 2021

Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

Newsroom
A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

Our groundbreaking science

targeting C3 offers the potential to provide comprehensive control of complement, a part of the immune system

Our Science
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

We aim to transform

treatment across a broad range of debilitating diseases driven by complement

Pipeline